Protara Therapeutics
$3.98
39
-$0.09-2.21% Today
Statistics
Day High
4.2
Day Low
3.97
52W High
7.82
52W Low
2.77
Volume
797,180
Avg. Volume
735,506
Mkt Cap
153.58M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30JulExpected
Expected EPS
-0.325714
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-89.19MNet Income
Analyst Ratings
25.67Average Price Target
The highest estimate is 27.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TARA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap155.93B
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Merck
MRK
Mkt Cap294.03B
AMGEN
AMGN
Mkt Cap191.7B
Pfizer
PFE
Mkt Cap149.38B
Novartis
NVS
Mkt Cap292.07B
Abbvie
ABBV
Mkt Cap402.35B
Roche
RHHBY
Mkt Cap332.67B
Astrazeneca
AZN
Mkt Cap277.22B
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
About
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Show more...
CEO
Mr. Jesse Shefferman
Employees
28
Country
United States
ISIN
US74365U1079
Listings
0 Comments
Share your thoughts
FAQ
What is Protara Therapeutics stock price today?▼
The current price of TARA is $3.98 USD — it has decreased by -2.21% in the past 24 hours. Watch Protara Therapeutics stock price performance more closely on the chart.
What is Protara Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Protara Therapeutics stocks are traded under the ticker TARA.
Is Protara Therapeutics stock price growing?▼
TARA stock has risen by +9.04% compared to the previous week, the month change is a -13.48% fall, over the last year Protara Therapeutics has showed a +33.56% increase.
What is Protara Therapeutics market cap?▼
Today Protara Therapeutics has the market capitalization of 153.58M
When is the next Protara Therapeutics earnings date?▼
Protara Therapeutics is going to release the next earnings report on July 30, 2026.
What were Protara Therapeutics earnings last quarter?▼
TARA earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.37 USD resulting in a +15.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protara Therapeutics revenue for the last year?▼
Protara Therapeutics revenue for the last year amounts to 0 USD.
What is Protara Therapeutics net income for the last year?▼
TARA net income for the last year is -89.19M USD.
How many employees does Protara Therapeutics have?▼
As of June 18, 2026, the company has 28 employees.
In which sector is Protara Therapeutics located?▼
Protara Therapeutics operates in the Health & Wellness sector.
When did Protara Therapeutics complete a stock split?▼
The last stock split for Protara Therapeutics was on January 10, 2020 with a ratio of 1:40.
Where is Protara Therapeutics headquartered?▼
Protara Therapeutics is headquartered in New York, United States.